Published in J Clin Oncol on January 12, 2009
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02
Adjuvant therapy for melanoma. Cancer J (2012) 1.01
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol (2009) 0.93
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med (2011) 0.88
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med (2010) 0.85
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One (2012) 0.82
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol (2013) 0.81
Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. Cancer Med (2015) 0.80
Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol (2009) 0.78
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
Adjuvant treatment of melanoma. ISRN Dermatol (2013) 0.78
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
Adjuvant interferon alfa for melanoma. Curr Oncol (2010) 0.75
Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma. J Clin Oncol (2009) 0.75
Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. Transl Oncol (2017) 0.75
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol (2002) 3.45
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet (2002) 2.78
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.09
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol (2005) 2.05
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2005) 1.91
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol (2008) 1.88
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol (2006) 1.80
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2009) 1.55
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol (2009) 1.50
Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist (2008) 1.48
Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One (2009) 1.45
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (2006) 1.43
Comparison of transthecal digital block and traditional digital block for anesthesia of the finger. Plast Reconstr Surg (2004) 1.43
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer (2008) 1.43
Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. Int J Cancer (2007) 1.35
Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma (2006) 1.33
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer (2003) 1.32
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer (2012) 1.30
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res (2010) 1.30
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2006) 1.26
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res (2009) 1.17
8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. Int J Cancer (2003) 1.14
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (2012) 1.11
Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys (2004) 1.11
Multifocal extranodal non-hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study. Oncologist (2005) 1.07
Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res (2009) 1.07
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res (2005) 1.06
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer (2012) 1.05
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer (2013) 1.04
Application of the pedicled anterolateral thigh flap to defects from the pelvis to the knee. Microsurgery (2006) 1.04
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer (2005) 1.02
Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res (2010) 1.02
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest (2005) 1.00